The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

This publication has 36 references indexed in Scilit:

• Model for Assessing Human Papillomavirus Vaccination Strategies
  Emerging Infectious Diseases, 2007
• Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK
  British Journal of Cancer, 2006
• Impact of Model, Methodological, and Parameter Uncertainty in the Economic Analysis of Vaccination Programs
  Medical Decision Making, 2006
• Chapter 13: Current findings from prophylactic HPV vaccine trials
  Vaccine, 2006
• Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK
  Current Medical Research and Opinion, 2006
• Cost-effectiveness of Extending Cervical Cancer Screening Intervals Among Women With Prior Normal Pap Tests
  Obstetrics & Gynecology, 2006
• Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and Italy
  JNCI Journal of the National Cancer Institute, 2005
• Interprovincial Differences in GDP Per Capita, Labour Productivity and Work Intensity: 1990-2003
  SSRN Electronic Journal, 2005
• Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis
  British Journal of Cancer, 2003
• Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
  New England Journal of Medicine, 2003